SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the appointment of Sarah M. Romano as chief financial officer, effective August 3, 2026. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised over $100 million during her career. She joins from Vicarious Surgical, another robotic surgery developer, where she led financial and operational initiatives to reduce cash burn and strengthen the balance sheet.
The appointment comes as SS Innovations pursues broader commercialization of its SSi Mantra robotic surgical platform and continues preparations for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM). The company is simultaneously expanding internationally, recently graduating the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program. SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.
Romano’s appointment adds public-company financial and capital markets experience at a critical juncture. The company is seeking FDA clearance for the SSi Mantra system, a key step toward entering the U.S. market, one of the largest for surgical robotics. Internationally, the company has been deploying the system and training surgeons, which could accelerate adoption in regions with growing demand for minimally invasive surgery.
The expansion of the training program signals SS Innovations’ commitment to building a skilled user base, which is often a barrier to adoption for new surgical technologies. By training surgeons from multiple countries, the company is positioning itself to capture market share in emerging markets where robotic surgery is less established. The graduation of the first class of cardiac robotic surgery trainees highlights the company’s focus on complex procedures that can benefit from robotic assistance.
The appointment of a CFO with a track record of raising capital and managing finances in the medtech sector may help SS Innovations navigate the capital-intensive process of regulatory approval and commercialization. The company’s stock is traded on NASDAQ under the symbol SSII, and further updates are available in the company’s newsroom (https://ibn.fm/SSII).
As robotic surgery continues to grow globally, SS Innovations’ progress with the SSi Mantra system could impact the competitive landscape. The company’s focus on cardiac surgery and training may differentiate it from established players. The success of its regulatory and commercial strategies will be closely watched by investors and healthcare providers.
Forward-looking statements in the announcement involve risks and uncertainties, including those detailed in the company’s filings with the SEC. The company undertakes no duty to update this information unless required by law.
